Bladder Recurrence Following the Treatment of Upper Tract Urothelial Carcinoma
DOI:
https://doi.org/10.31584/jhsmr.2021807Keywords:
bladder recurrence, nephroureterectomy, upper tract urothelial carcinomaAbstract
Objective: Although, upper tract urothelial carcinoma (UTUC) is rare it is associated with a high mortality rate and frequently, followed by bladder recurrence after radical surgery. Hence, this study aimed to identify the rate of bladder recurrence and its predictive factors.
Material and Methods: We reviewed the medical records of 104 patients, who were diagnosed with UTUC and had radical nephroureterectomy (RNU), at the King Chulalongkorn Memorial Hospital. We excluded patients who have concurrent bladder cancer, or had a history of bladder cancer. Various clinicopathological factors were analyzed using the log-rank test and Cox proportional hazard model.
Results: The mean age at diagnosis of UTUC was 68 years, and one-third of the patients were diagnosed with pathological T3 (33.7%). The mean follow-up duration was 56 months. Bladder recurrence occurred in 39 out of 104 patients (37.5%), and the median time to recurrence was 5.8 months (interquartile range 3.6 to 11.0 months). Tumor location in the distal ureter (p-value=0.038) and history of diagnostic ureteroscopy (p-value=0.004) were significantly associated with bladder recurrence in the univariate model. However, only the history of diagnostic ureteroscopy remained significant in the multivariate analysis (p-value=0.023).
Conclusion: Bladder recurrence, following RNU, occurs in one-third of patients. Potential predictive factors may include history of diagnostic ureteroscopy, and the tumor location being in the distal ureter.
References
Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018;73:111-22.
Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS. Bladder cancer after managing upper urinary trac transitional cell carcinoma: predictive factors and pathology. BJU Int 2005;96:1031-5.
Xylinas E, Colin P, Audenet F, Phe V, Cormier L, Cussenot O, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol 2013;31:61-8.
Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 2008;71:123-7.
Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, et al. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology 2000;55: 663-7.
Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279-83.
Pieras E, Frontera G, Ruiz X, Vicens A, Ozonas M, Piza P. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int 2010;106: 1319-23.
Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int 2006;98:1181-6.
Huang WW, Huang HY, Liao AC, Shiue YL, Tai HL, Lin CM, et al. Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol Int 2009;59:642-9.
Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int 2008; 101:1368-74.
Chung SD, Huang KH, Lai MK, Huang CY, Chen CH, Pu YS, et al. CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis 2007;50:743-53.
Kobayashi Y, Saika T, Miyaji Y, Saegusa M, Arata R, Akebi N, et al. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol 2012;30:271-5.
Sung HH, Jeon HG, Han DH, Jeong BC, Seo SI, Lee HM, et al. Diagnostic Ureterorenoscopy Is Associated with Increased Intravesical Recurrence following Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. PloS One 2015;10: e0139976.
Lee HY, Yeh HC, Wu WJ, He JS, Huang CN, Ke HL, et al. The diagnostic ureteroscopy before radical nephroureterectomy in upper urinary tract urothelial carcinoma is not associated with higher intravesical recurrence. World J Surg Oncol 2018;16:135.
Ishikawa S, Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, et al. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. J Urol 2010;184:883-7.
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. New York: Springer; 2017.
Liu P, Su XH, Xiong GY, Li XS, Zhou LQ. Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma is Independently Associated with Intravesical Recurrence after Radical Nephroureterectomy. Int Braz J Urol 2016;42:1129-35.
Lee JK, Kim KB, Park YH, Oh JJ, Lee S, Jeong CW, et al. Correlation Between the Timing of Diagnostic Ureteroscopy and Intravesical Recurrence in Upper Tract Urothelial Cancer. Clin Genitourin Cancer 2016;14:e37-41.
Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010;105:812-7.
Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?. J Urol 2010;183:56-61.
Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013;31:1422-7.
O'Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60: 703-10.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
